List of Votrient drug patents

Votrient is owned by Novartis.

Votrient contains Pazopanib Hydrochloride.

Votrient has a total of 1 drug patent out of which 0 drug patents have expired.

Votrient was authorised for market use on 19 October, 2009.

Votrient is available in tablet;oral dosage forms.

The generics of Votrient are possible to be released after 19 October, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7105530 NOVARTIS Pyrimidineamines as angiogenesis modulators
Oct, 2023

(8 months from now)

Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2009

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in